Table 11.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Heart Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	2,363	2,343	2,293	2,348	2,188	2,199	2,202	2,155	2,057	2,016
Tx with Antirejection Treatments	955	854	871	979	916	900	850	800	657	522
Antibodies										
Any in Category	20.8%	18.1%	19.3%	21.2%	17.7%	16.3%	15.5%	17.5%	18.4%	14.9%
ALG	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	8.1%	5.4%	7.9%	7.3%	6.3%	4.6%	3.9%	4.0%	4.6%	2.7%
OKT3	14.5%	13.9%	13.1%	14.9%	7.4%	5.1%	5.8%	6.9%	4.1%	3.1%
Thymoglobulin	0.0%	0.0%	0.1%	0.2%	2.0%	3.8%	4.9%	6.4%	7.5%	8.8%
Zenapax	0.0%	0.0%	0.1%	0.8%	2.5%	3.0%	2.5%	1.5%	2.0%	0.8%
Simulect	0.0%	0.0%	0.0%	0.1%	0.9%	2.0%	0.4%	0.4%	1.4%	0.8%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%
Corticosteroids										
Any in Category	92.6%	88.3%	88.6%	87.9%	91.3%	92.3%	92.7%	92.1%	92.5%	92.3%
Steroids	92.6%	88.3%	88.6%	87.9%	91.3%	92.3%	92.7%	92.1%	92.5%	92.3%
Antimetabolites										
Any in Category	6.6%	5.4%	7.6%	6.5%	4.6%	4.4%	2.0%	3.0%	3.5%	1.7%
Cytoxan	1.8%	1.8%	3.6%	2.5%	2.1%	1.7%	0.5%	0.9%	1.7%	1.3%
Methotrexate	4.9%	3.6%	4.1%	4.3%	2.6%	2.8%	1.5%	2.1%	1.8%	0.4%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.